– Indivumed evolves to Indivumed Therapeutics to focus on data and AI-driven advancement of precision oncology
Sale of Indivumed Services Business to Crown Bioscience Enables Creation of Oncology RD Powerhouse
HAMBURG, Germany, April 4, 2023 /PRNewswire/ — After 20 years as one of the first personalized oncology companies, Indivumed today announced its evolution to Indivumed Therapeutics following the acquisition of Indivumed Services GmbH and its CRO service offerings by part of Crown Bioscience. Indivumed Therapeutics emerges as an oncology biotechnology company focused entirely on the discovery and validation of biomarkers and therapeutic targets, drug development, and clinical trial performance. Indivumed Therapeutics will continue to use its global clinical network for clinical data collection and biological samples to grow its unique multi-omics database using its AI-powered discovery and development platform for novel therapies in oncology.
“Indivumed’s success over the past 20 years has been made possible by our consistent focus on highly standardized clinical data and sample collection across a global clinical network. It is amazing to see how our clinically anchored quality approach, combined with the AI-powered data analytics pays off and drives reliable target discovery with incredible speed Now, we partner with biotech, pharmaceutical and diagnostic companies to provide a wide range of novel therapeutic targets for their development programs with a high probability of clinical success. We ourselves will focus on different targets for lead compound and development of diagnostic signatures to directly impact cancer therapy,” explained Professor Hartmut Juhl, MD, CEO and founder of Indivumed.
Indivumed Therapeutics will accelerate cancer drug development through its AI-powered analysis platform, nRavel®, by linking in-silico target discovery and development with patient-derived tumor models for lead and target compound validation later. The company will drive RD in multi-omics oncology by leveraging its partnerships with leading cancer clinics in Europe, the Americas, and Asia to further expand its database and drive preclinical and clinical development programs.
Indivumed Therapeutics has already identified numerous potential diagnostic and predictive biomarkers and targets, several of which have been selected for biologic validation and lead compound development. Several patents have already been filed and Indivumed Therapeutics is continuing the process of identifying additional targets and biomarkers. The commercial focus will be the licensing of validated targets, lead compounds and biomarkers at different stages of development. All of this in close collaboration with academic, biotech and pharmaceutical companies to increase the likelihood of achieving the ultimate goal of advancing precision oncology for the cure of cancer.
About Individuald Therapeutics
Emerging as a result of Indivumed’s twenty years of success and innovation as a leading precision oncology company, Indivumed Therapeutics is fully focused on AI-driven biomarker and therapeutic target discovery, target validation, preclinical drug development and clinical validation. A global clinical network of leading cancer clinics and hospitals in Europe, the Americas and Asia enables standardized collection of biological samples and clinical data into a comprehensive multi-omics database. The unique AI-powered data discovery machine nRavel® together with patient-derived cell models and its integration into a global clinical network provides a unique diagnostic and drug development platform for precision oncology. For more information, visit www.indivumed-therapeutics.com
Media Contact: Patrick Renegar 919-623-5577 prenegar@livewiredc.com
Logo – https://mma.prnewswire.com/media/1002609…
View original content: https://www.prnewswire.com/news-releases/indivumed-evoluciona-a-indivumed-therapeutics-para-centrarse-en-los-datos-y-la-oncologia-de-precision-301788489.html
